| Ytd | 29.80% | |
| 1y | 85.16% |
| Open | Prev Close | 13.85 | Low | High | Mkt Cap | 18.59M | |||
| Vol | 0.00 | Avg Vol | 52.33K | EPS | -142.72 | P/E | -0.10 | Forward P/E | -0.40 |
| Beta | -0.25 | Short Ratio | 0.29 | Inst. Own | 8.81% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-08 | 50-d Avg | 21.49 | 200-d Avg | 16.71 | 1yr Est | 4.13 |
SNSE News
AUSTIN, Texas--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it
Wall Street analysts changed outlook on top names like MKTX, PRCT, VOD, and JILL. See ratings page a
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Com
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the first quarter e
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial result
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company ma
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial result
Sensei Biotherapeutics (NASDAQ: SNSE - Get Free Report) is expected to be announcing its Q4 2025 res
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider. com News Commentary
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE - Get Free Report) was the recipient of a large increase
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective
SNSE up on acquisition of Faeth Therapeutics, $200M private placement, and addition of PIKTOR to pip
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acq
Cynata Therapeutics (OTCMKTS:CYYNF - Get Free Report) and Sensei Biotherapeutics (NASDAQ: SNSE - Get
PARIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics SAS (Egle), a clinical-stage biotechnolog
Sensei Biotherapeutics surged in after-hours trading Thursday, with strong recent gains and ongoing
BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical st
BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-st
On Thursday, 369 companies hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
On Friday, 431 companies hit new 52-week lows.
On Monday, 147 stocks hit new 52-week lows.
During Thursday, 166 stocks hit new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.